• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

开发和验证一种用于在意大利全地区病理注册中心识别非小细胞肺癌的病例发现算法。

Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry.

机构信息

INSERM, BPH, U1219, Team Pharmacoepidemiology, University of Bordeaux, Bordeaux, France.

Department of Medical Science, Surgery and Neuroscience, University of Siena, Siena, Italy.

出版信息

PLoS One. 2022 Jun 8;17(6):e0269232. doi: 10.1371/journal.pone.0269232. eCollection 2022.

DOI:10.1371/journal.pone.0269232
PMID:35675338
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9176782/
Abstract

PURPOSE

To develop and validate a case-finding algorithm for the identification of Non-Small Cell Lung Cancer (NSCLC) cases in a region-wide Italian pathology registry (PR).

MATERIALS AND METHODS

Data collected between 2009 and 2017 in the PR and the Pharmacy Database of the University Hospital of Siena and the PR of Tuscany region were used. A NSCLC-identification algorithm based on free-text keywords and SNOMED morphology and topography codes was designed and tested on data from Siena: indication for drug use (i.e. NSCLC) was the reference standard for sensitivity (SE); positive predictive value (PPV) was estimated through manual review. Algorithm modifications were then tested to improve algorithm performance: PPV was calculated against validated dataset from PR of Siena; a range of SE [min-max] was estimated in PR of Tuscany using analytical formulae that assumed NSCLC incidence equal either to 80% or 90% of overall lung cancer incidence recorded in Tuscany. The algorithm modification with the best performance was chosen as the final version of the algorithm. A random sample of 200 cases was extracted from the PR of Tuscany for manual review.

RESULTS

The first version of the algorithm showed a PPV of 74.7% and SE of 79% in PR of Siena. The final version of the algorithm had a SE in PR of Tuscany that grew with calendar time (2009 = [24.7%-28%]; 2017 = [57.9%-65.1%]) and a PPV of 93%.

CONCLUSIONS

The final NSCLC-finding algorithm showed with very high PPV. SE was in line with the expected contribution of PR to overall cases captured in the regional Cancer Registry, with a trend of increase over calendar time. Given the promising algorithm validity and the wide use of SNOMED terminology in electronic pathology records, the proposed algorithm is expected to be easily adapted to other electronic databases for (pharmaco)epidemiology purposes.

摘要

目的

开发和验证一种在意大利区域病理登记处(PR)中识别非小细胞肺癌(NSCLC)病例的病例发现算法。

材料和方法

使用了 2009 年至 2017 年在 PR 和锡耶纳大学医院药房数据库以及托斯卡纳地区 PR 中收集的数据。设计了一种基于自由文本关键词和 SNOMED 形态和拓扑代码的 NSCLC 识别算法,并在锡耶纳的数据上进行了测试:药物使用的适应症(即 NSCLC)是敏感性(SE)的参考标准;阳性预测值(PPV)通过手动审查进行估计。然后对算法进行修改以提高算法性能:在锡耶纳 PR 的验证数据集上计算 PPV;在托斯卡纳 PR 中,使用假设 NSCLC 发生率等于托斯卡纳记录的所有肺癌发生率的 80%或 90%的分析公式来估计 SE 的范围[最小-最大]。选择性能最佳的算法修改作为算法的最终版本。从托斯卡纳 PR 中随机抽取 200 例进行手动审查。

结果

算法的第一个版本在锡耶纳 PR 中显示出 74.7%的 PPV 和 79%的 SE。最终版本的算法在托斯卡纳 PR 中的 SE 随着日历时间的推移而增长(2009 年= [24.7%-28%];2017 年= [57.9%-65.1%]),PPV 为 93%。

结论

最终的 NSCLC 发现算法具有非常高的 PPV。SE 与 PR 对区域癌症登记处中捕获的所有病例的预期贡献一致,随着日历时间的推移呈上升趋势。鉴于算法有效性的前景以及 SNOMED 术语在电子病理学记录中的广泛应用,预计该算法将易于适应其他电子数据库,以用于(药物)流行病学目的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95bf/9176782/11536c6247be/pone.0269232.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95bf/9176782/11536c6247be/pone.0269232.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95bf/9176782/11536c6247be/pone.0269232.g001.jpg

相似文献

1
Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry.开发和验证一种用于在意大利全地区病理注册中心识别非小细胞肺癌的病例发现算法。
PLoS One. 2022 Jun 8;17(6):e0269232. doi: 10.1371/journal.pone.0269232. eCollection 2022.
2
How to discriminate non-small cell lung cancer (NSCLC) cases from an Italian administrative database? A retrospective, secondary data use study for evaluating a novel algorithm performance.如何从意大利行政数据库中区分非小细胞肺癌(NSCLC)病例?一项用于评估新型算法性能的回顾性、二次数据使用研究。
BMJ Open. 2021 Sep 24;11(9):e048188. doi: 10.1136/bmjopen-2020-048188.
3
Validation of an Updated Algorithm to Identify Patients With Incident Non-Small Cell Lung Cancer in Administrative Claims Databases.验证一种用于在行政索赔数据库中识别新发非小细胞肺癌患者的更新算法。
JCO Clin Cancer Inform. 2024 Mar;8:e2300165. doi: 10.1200/CCI.23.00165.
4
Identifying incident colorectal and lung cancer cases in health service utilisation databases in Australia: a validation study.在澳大利亚医疗服务利用数据库中识别结直肠癌和肺癌新发病例:一项验证研究。
BMC Med Inform Decis Mak. 2017 Feb 27;17(1):23. doi: 10.1186/s12911-017-0417-5.
5
Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications.意大利行政医疗保健数据在描述注射用抗肿瘤药物实际使用情况方面的有效性:以西耶纳大学医院接受肿瘤血液学适应症治疗患者使用利妥昔单抗为例的研究
Front Oncol. 2023 May 31;13:1059109. doi: 10.3389/fonc.2023.1059109. eCollection 2023.
6
Validation study of colorectal cancer diagnosis in the Spanish primary care database, BIFAP.BIFAP 西班牙初级保健数据库中结直肠癌诊断的验证研究。
Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):209-216. doi: 10.1002/pds.4686. Epub 2018 Dec 12.
7
Validation of a Case-Finding Algorithm for Identifying Patients with Non-small Cell Lung Cancer (NSCLC) in Administrative Claims Databases.行政索赔数据库中用于识别非小细胞肺癌(NSCLC)患者的病例发现算法的验证
Front Pharmacol. 2017 Nov 30;8:883. doi: 10.3389/fphar.2017.00883. eCollection 2017.
8
Validation of Case Finding Algorithms for Hepatocellular Cancer From Administrative Data and Electronic Health Records Using Natural Language Processing.使用自然语言处理技术从行政数据和电子健康记录中验证肝细胞癌病例发现算法
Med Care. 2016 Feb;54(2):e9-14. doi: 10.1097/MLR.0b013e3182a30373.
9
Validity of Natural Language Processing for Ascertainment of and Test Results in SEER Cases of Stage IV Non-Small-Cell Lung Cancer.自然语言处理在监测美国国立癌症研究所监测、流行病学和最终结果(SEER)项目中IV期非小细胞肺癌病例的[具体内容缺失]和检测结果方面的有效性。
JCO Clin Cancer Inform. 2019 May;3:1-15. doi: 10.1200/CCI.18.00098.
10
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.

引用本文的文献

1
The validity of pathology codes for biopsy-confirmed kidney disease in the Danish National Patobank.丹麦国家病理库中经活检确诊的肾病病理编码的有效性。
Clin Kidney J. 2024 Jul 9;17(8):sfae203. doi: 10.1093/ckj/sfae203. eCollection 2024 Aug.
2
Development and Validation of a META-Algorithm to Identify the Indications of Use of Biological Drugs Approved for the Treatment of Immune-Mediated Inflammatory Diseases from Claims Databases: Insights from the VALORE Project.从索赔数据库中识别获批用于治疗免疫介导性炎症疾病的生物药物使用指征的META算法的开发与验证:VALORE项目的见解
Clin Epidemiol. 2024 Jun 4;16:395-407. doi: 10.2147/CLEP.S445120. eCollection 2024.

本文引用的文献

1
Validation of algorithms in studies based on routinely collected health data: general principles.基于常规收集的健康数据的研究中算法的验证:一般原则。
Am J Epidemiol. 2024 Nov 4;193(11):1612-1624. doi: 10.1093/aje/kwae071.
2
First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective.非可切除性非小细胞肺癌患者的一线药物治疗与生存情况:一项具有性别前瞻性的真实病例研究
Cancers (Basel). 2021 Dec 5;13(23):6129. doi: 10.3390/cancers13236129.
3
Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data.
基于常规电子医疗保健数据的肺癌靶向和免疫治疗的真实世界应用:研究的范围综述。
Int J Environ Res Public Health. 2021 Jul 19;18(14):7679. doi: 10.3390/ijerph18147679.
4
Outcome misclassification: Impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence.结局偏倚:影响、药物流行病学数据库研究中的常规做法,以及校正风险比或累积发生率有偏估计的在线辅助工具。
Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1450-1455. doi: 10.1002/pds.5109. Epub 2020 Aug 28.
5
Disease misclassification in electronic healthcare database studies: Deriving validity indices-A contribution from the ADVANCE project.电子医疗保健数据库研究中的疾病分类错误:有效性指标的推导——来自 ADVANCE 项目的贡献。
PLoS One. 2020 Apr 22;15(4):e0231333. doi: 10.1371/journal.pone.0231333. eCollection 2020.
6
Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project.多数据库研究中结局分类错误的量化:以 ADVANCE 项目中百日咳为例。
Vaccine. 2020 Dec 22;38 Suppl 2:B56-B64. doi: 10.1016/j.vaccine.2019.07.045. Epub 2019 Oct 31.
7
Non-small cell lung cancer: current treatment and future advances.非小细胞肺癌:当前治疗与未来进展。
Transl Lung Cancer Res. 2016 Jun;5(3):288-300. doi: 10.21037/tlcr.2016.06.07.
8
The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.临床试验参与在癌症研究中的作用:障碍、证据与策略
Am Soc Clin Oncol Educ Book. 2016;35:185-98. doi: 10.1200/EDBK_156686.
9
The impact of electronic health record usage on cancer registry systems in Alabama.电子健康记录的使用对阿拉巴马州癌症登记系统的影响。
Perspect Health Inf Manag. 2012;9(Spring):1f. Epub 2012 Apr 1.
10
The role of informatics in promoting patient-centered care.信息学在促进以患者为中心的护理中的作用。
Cancer J. 2011 Jul-Aug;17(4):211-8. doi: 10.1097/PPO.0b013e318225ff89.